Robert Hazlett
Stock Analyst at BTIG
(0.87)
# 2,812
Out of 4,413 analysts
28
Total ratings
34.48%
Success rate
-16.38%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $38 → $21 | $7.40 | +183.78% | 2 | Dec 8, 2023 | |
| SEEL Seelos Therapeutics | Maintains: Buy | $330 → $120 | $0.28 | +42,910.75% | 5 | May 15, 2023 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $5.16 | +287.60% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $73.76 | +32.86% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $9.98 | +501.20% | 2 | Oct 5, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Neutral | n/a | $1.46 | - | 1 | Mar 15, 2022 | |
| GRTX Galera Therapeutics | Upgrades: Buy | n/a | $0.19 | - | 2 | Dec 15, 2021 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | n/a | $6.38 | - | 1 | Aug 25, 2021 | |
| CMPS COMPASS Pathways | Initiates: Buy | n/a | $8.57 | - | 1 | May 27, 2021 | |
| TCON TRACON Pharmaceuticals | Upgrades: Buy | $280 | $1.73 | +16,084.97% | 2 | Apr 16, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | n/a | $20.34 | - | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | n/a | $71.81 | - | 1 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | n/a | $0.43 | - | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Initiates: Buy | n/a | $1.26 | - | 1 | Dec 7, 2017 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | n/a | $11.35 | - | 2 | Oct 16, 2017 |
Aura Biosciences
Dec 8, 2023
Maintains: Buy
Price Target: $38 → $21
Current: $7.40
Upside: +183.78%
Seelos Therapeutics
May 15, 2023
Maintains: Buy
Price Target: $330 → $120
Current: $0.28
Upside: +42,910.75%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $5.16
Upside: +287.60%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $73.76
Upside: +32.86%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $9.98
Upside: +501.20%
Nektar Therapeutics
Mar 15, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Galera Therapeutics
Dec 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $0.19
Upside: -
Rani Therapeutics Holdings
Aug 25, 2021
Initiates: Buy
Price Target: n/a
Current: $6.38
Upside: -
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: n/a
Current: $8.57
Upside: -
TRACON Pharmaceuticals
Apr 16, 2021
Upgrades: Buy
Price Target: $280
Current: $1.73
Upside: +16,084.97%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: n/a
Current: $20.34
Upside: -
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: n/a
Current: $71.81
Upside: -
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: n/a
Current: $0.43
Upside: -
Akebia Therapeutics
Dec 7, 2017
Initiates: Buy
Price Target: n/a
Current: $1.26
Upside: -
KalVista Pharmaceuticals
Oct 16, 2017
Maintains: Buy
Price Target: n/a
Current: $11.35
Upside: -